Abcam and The Michael J. Fox Foundation for Parkinson’s Research
In collaboration with The Michael J. Fox Foundation Abcam are providing critical reagents to key targets to break down Parkinson’s research barriers.
Researchers rely on critical tools, including reagents and pre-clinical models, to understand the cause and mechanisms underlying Parkinson’s disease and to develop effective treatments. When such tools are lacking, investigators must often make their own, wasting time and resources that would be better spent on studying Parkinson’s disease. Many existing tools may also lack sufficient quality control data, are difficult to obtain by the wider research community, or may come with restrictive license terms and fees that hinder drug makers’ ability to use them. Promoting the generation and availability of critical research tools is a key way to accelerate therapeutic development for Parkinson’s patients.
Abcam is paving the way for Parkinson’s research breakthroughs by collaborating with The Michael J. Fox Foundation to provide critical reagents to key targets.
To learn more please visit: